/Resmed%20Inc_%20HQ%20photo-by%20JHVEPhoto%20via%20iStock.jpg)
San Diego, California-based ResMed Inc. (RMD) develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare market. With a market cap of $36.9 billion, the company operates in two segments, Sleep and Respiratory Care, and Software as a Service.
Companies worth $10 billion or more are generally described as "large-cap stocks." RMD falls squarely into this category, with its market cap exceeding this threshold, reflecting its substantial size and influence in the Medical Instruments & Supplies industry. The company benefits from its offerings in the worldwide market for generators, masks, and related accessories for the treatment of sleep-disordered breathing (SDB) and other respiratory disorders.
Shares of the company touched their 52-week high of $263.05 on Jan. 30 and have fallen 5.2% from that peak. Shares of RMD have surged 13.5% over the past three months, outperforming the Health Care Select Sector SPDR Fund’s (XLV) 5.4% decline over the same time frame.
Longer term, RMD stock is up 9% on a YTD basis, outperforming XLV’s 1.1% decline. Moreover, shares of the company have surged 17.4% over the past 52 weeks, compared to XLV’s 6.7% decline over the same time frame.
To confirm its bullish trend, RMD has been trading above its 200-day and 50-day moving averages since late April.
RMD shares grew 10.1% following the release of its Q3 earnings on Apr. 23. The company’s revenues climbed 7.5% year over year to $1.3 billion, surpassing estimates, driven by 8% growth in the Sleep and Breathing Health segment and 9% in Residential Care Software. Moreover, its adjusted EPS for the quarter increased 11.3% year-over-year to $2.37, surpassing the consensus estimates marginally.
Its peer, Becton, Dickinson and Company (BDX), has lagged behind the company, with its shares declining 24.1% in 2025 and 25.8% over the past year.
Among the 17 analysts covering the RMD stock, the consensus rating is a “Moderate Buy.” Its mean price target of $258.75 suggests a 3.8% upside potential from current price levels.
On the date of publication, Kritika Sarmah did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.
